E3 ligase substrate adaptor SPOP fine-tunes the UPR of pancreatic β cells
Genes & Development · 2025
DOI: 10.1101/gad.352010.124 ↗Kurz gefasst
Fachartikel in der Zeitschrift Genes & Development, 2025. Verfasst von Alexis U Oguh und 16 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Diabetes, Obesity, and Metabolism, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Penns…. Hauptthemen laut MEDLINE: Insulin-Secreting Cells, Unfolded Protein Response, Repressor Proteins, Nuclear Proteins. Die Arbeit nennt 109 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, National Institutes of Health, Diabetes Research Center at the University of Pennsylvania.
Abstract (Originalsprache)
The Cullin-3 E3 ligase adaptor protein SPOP targets proteins for ubiquitination and proteasomal degradation. We previously established the β-cell transcription factor (TF) and human diabetes gene PDX1 as an SPOP substrate, suggesting a functional role for SPOP in the β cell. Here, we generated a β-cell-specific Spop deletion mouse strain ( Spop βKO ) and found that Spop is necessary to prevent aberrant basal insulin secretion and for maintaining glucose-stimulated insulin secretion through impacts on glycolysis and glucose-stimulated calcium flux. Integration of proteomic, TF-regulatory gene network, and biochemical analyses identified XBP1 as a functionally important SPOP substrate in pancreatic β cells. Furthermore, loss of SPOP strengthened the IRE1α–XBP1 axis of unfolded protein response (UPR) signaling. ER stress promoted proteasomal degradation of SPOP, supporting a model whereby SPOP fine-tunes XBP1 activation during the UPR. These results position SPOP as a regulator of β-cell function and proper UPR activation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute for Diabetes, Obesity, and Metabolism, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19146, USA.
- Department of Molecular Physiology and Biophysics, Vanderbilt University, Nashville, Tennessee 37232, USA.
- Proteomics Core Facility, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania 19146, USA.
- Department of Cell and Developmental Biology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19146, USA.
- Department of Pediatrics and Cell and Developmental Biology, Barbara Davis Center for Diabetes, University of Colorado Anschutz Medical Campus, Aurora, Colorado 80045, USA.
- Department of Biochemistry and Biophysics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19146, USA.
ORCID-Profile: Lori Sussel
Förderung
- NIDDK NIH HHS
- National Institutes of Health
- Diabetes Research Center at the University of Pennsylvania
Zitieren
APA
Oguh, A. U., Haemmerle, M. W., Sen, S., Rozo, A. V., Shrestha, S., Cartailler, J. P., Fazelinia, H., Ding, H., Preza, S., Yang, J., Yang, X., Sussel, L., Alvarez-Dominguez, J. R., Doliba, N., Spruce, L. A., Arrojo E Drigo, R., & Stoffers, D. A. (2025). E3 ligase substrate adaptor SPOP fine-tunes the UPR of pancreatic β cells. Genes & Development. https://doi.org/10.1101/gad.352010.124
Vancouver
Oguh AU, Haemmerle MW, Sen S, Rozo AV, Shrestha S, Cartailler JP, et al. E3 ligase substrate adaptor SPOP fine-tunes the UPR of pancreatic β cells. Genes & Development. 2025. doi:10.1101/gad.352010.124
BibTeX
@article{Oguh2025,
author = {Oguh, Alexis U and Haemmerle, Matthew W and Sen, Sabyasachi and Rozo, Andrea V and Shrestha, Shristi and Cartailler, Jean-Philippe and Fazelinia, Hossein and Ding, Hua and Preza, Sam and Yang, Juxiang and Yang, Xiaodun and Sussel, Lori and Alvarez-Dominguez, Juan R and Doliba, Nicolai and Spruce, Lynn A and Arrojo E Drigo, Rafael and Stoffers, Doris A},
title = {E3 ligase substrate adaptor SPOP fine-tunes the UPR of pancreatic β cells},
journal = {Genes & Development},
year = {2025},
doi = {10.1101/gad.352010.124}
}
EUVIMED